Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

NCT00230178 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

280

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumor Lysis Syndrome
Cancer
Hyperuricemia

Interventions

DRUG: Rasburicase (SR29142)
DRUG: Allopurinol

Sponsor

Sanofi